"Lifitegrast (Dry Eye Syndrome) - Analysis and Forecasts to 2022" - New Market Report
GlobalData’s pharmaceuticals report, “Lifitegrast (Dry Eye Syndrome) – Analysis and Forecasts to 2022” provides Lifitegrast sales forecasts for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2016-2022). The report also includes information on Dry Eye Syndrome. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor...
View full press release